FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224249124> ?p ?o ?g. }

• W4224249124 endingPage "1821" @default.
• W4224249124 startingPage "1815" @default.
• W4224249124 abstract "For patients with metastatic castration-resistant prostate cancer (mCRPC), no reliable biomarkers for predicting therapeutic response or assisting in treatment selection and sequencing are currently available. Using the recent European Association of Urology and European Association of Nuclear Medicine recommendations, we aimed to compare response assessment between prostate-specific membrane antigen (PSMA) PET/CT and conventional imaging in mCRPC patients starting first-line treatment with a novel hormonal agent (NHA) and to perform a sequential comparative analysis of PSMA PET/CT-derived parameters after 4 and 12 wk of therapy. Methods: Data from 18 mCRPC patients who started NHA treatment and underwent 68Ga-PSMA-11 PET/CT before therapy initiation (baseline), at week 4 (W4), and at week 12 (W12) in addition to conventional imaging (bone scintigraphy, CT) at baseline and W12 were retrospectively included. PET/CT images were quantitatively analyzed for maximum and mean SUV and total PSMA ligand-positive lesions. Comparative analysis of PET/CT-derived parameters was performed, and patients were classified as having nonprogressive disease or progressive disease (PD) according to 68Ga-PSMA-11 PET/CT, prostate-specific antigen, and conventional imaging criteria. Results: Treatment response was evaluable by 68Ga-PSMA-11 PET/CT in 16 of 18 patients (89%) and by conventional imaging in 11 of 18 patients (61%). Five of 16 patients classified as having PD by 68Ga-PSMA-11 PET/CT at W12 had already met progression criteria at W4, and substantial agreement was observed between W4 and W12 (κ, 0.74) 68Ga-PSMA-11 PET/CT results. Nonetheless, 2 of 16 patients (13%) were incorrectly classified as having PD because of a flare phenomenon on PSMA PET/CT that disappeared at W12. Conclusion: Volumetric assessments of 68Ga-PSMA-11 PET/CT imaging can improve response evaluation in NHA-treated patients with mCRPC. Although early response assessments at W4 need to be approached with caution because of flare, 68Ga-PSMA-11 PET/CT imaging at W4 and W12 revealed substantial agreement in therapy response assessments; these findings warrant further investigation to distinguish PD from flare at W4 and help improve the understanding of resistance to therapy." @default.
• W4224249124 created "2022-04-26" @default.
• W4224249124 creator A5016791565 @default.
• W4224249124 creator A5043698082 @default.
• W4224249124 creator A5047006962 @default.
• W4224249124 creator A5057476844 @default.
• W4224249124 creator A5065371356 @default.
• W4224249124 creator A5076200732 @default.
• W4224249124 date "2022-04-21" @default.
• W4224249124 modified "2023-10-12" @default.
• W4224249124 title "Using⁶⁸Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice" @default.
• W4224249124 cites W2019607817 @default.
• W4224249124 cites W2026280768 @default.
• W4224249124 cites W2040617334 @default.
• W4224249124 cites W2278392405 @default.
• W4224249124 cites W2470255787 @default.
• W4224249124 cites W2614800517 @default.
• W4224249124 cites W2740524391 @default.
• W4224249124 cites W2769219206 @default.
• W4224249124 cites W2801497722 @default.
• W4224249124 cites W2892965490 @default.
• W4224249124 cites W2895593497 @default.
• W4224249124 cites W2903950335 @default.
• W4224249124 cites W2921789984 @default.
• W4224249124 cites W2922269098 @default.
• W4224249124 cites W2951387977 @default.
• W4224249124 cites W2963473092 @default.
• W4224249124 cites W2975801492 @default.
• W4224249124 cites W3010388685 @default.
• W4224249124 cites W3012827461 @default.
• W4224249124 cites W3012831189 @default.
• W4224249124 cites W3019914727 @default.
• W4224249124 cites W3040491196 @default.
• W4224249124 cites W3042383619 @default.
• W4224249124 cites W3083964465 @default.
• W4224249124 cites W3086499088 @default.
• W4224249124 cites W3136360860 @default.
• W4224249124 cites W4213129631 @default.
• W4224249124 cites W4225884176 @default.
• W4224249124 doi "https://doi.org/10.2967/jnumed.121.263611" @default.
• W4224249124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35450960" @default.
• W4224249124 hasPublicationYear "2022" @default.
• W4224249124 type Work @default.
• W4224249124 citedByCount "5" @default.
• W4224249124 countsByYear W42242491242023 @default.
• W4224249124 crossrefType "journal-article" @default.
• W4224249124 hasAuthorship W4224249124A5016791565 @default.
• W4224249124 hasAuthorship W4224249124A5043698082 @default.
• W4224249124 hasAuthorship W4224249124A5047006962 @default.
• W4224249124 hasAuthorship W4224249124A5057476844 @default.
• W4224249124 hasAuthorship W4224249124A5065371356 @default.
• W4224249124 hasAuthorship W4224249124A5076200732 @default.
• W4224249124 hasBestOaLocation W42242491241 @default.
• W4224249124 hasConcept C121608353 @default.
• W4224249124 hasConcept C126322002 @default.
• W4224249124 hasConcept C126838900 @default.
• W4224249124 hasConcept C127077266 @default.
• W4224249124 hasConcept C143998085 @default.
• W4224249124 hasConcept C20417620 @default.
• W4224249124 hasConcept C2775842073 @default.
• W4224249124 hasConcept C2776049877 @default.
• W4224249124 hasConcept C2776235491 @default.
• W4224249124 hasConcept C2780192828 @default.
• W4224249124 hasConcept C2989005 @default.
• W4224249124 hasConcept C2993559085 @default.
• W4224249124 hasConcept C71924100 @default.
• W4224249124 hasConceptScore W4224249124C121608353 @default.
• W4224249124 hasConceptScore W4224249124C126322002 @default.
• W4224249124 hasConceptScore W4224249124C126838900 @default.
• W4224249124 hasConceptScore W4224249124C127077266 @default.
• W4224249124 hasConceptScore W4224249124C143998085 @default.
• W4224249124 hasConceptScore W4224249124C20417620 @default.
• W4224249124 hasConceptScore W4224249124C2775842073 @default.
• W4224249124 hasConceptScore W4224249124C2776049877 @default.
• W4224249124 hasConceptScore W4224249124C2776235491 @default.
• W4224249124 hasConceptScore W4224249124C2780192828 @default.
• W4224249124 hasConceptScore W4224249124C2989005 @default.
• W4224249124 hasConceptScore W4224249124C2993559085 @default.
• W4224249124 hasConceptScore W4224249124C71924100 @default.
• W4224249124 hasIssue "12" @default.
• W4224249124 hasLocation W42242491241 @default.
• W4224249124 hasLocation W42242491242 @default.
• W4224249124 hasLocation W42242491243 @default.
• W4224249124 hasOpenAccess W4224249124 @default.
• W4224249124 hasPrimaryLocation W42242491241 @default.
• W4224249124 hasRelatedWork W1978361053 @default.
• W4224249124 hasRelatedWork W1981161260 @default.
• W4224249124 hasRelatedWork W1987567565 @default.
• W4224249124 hasRelatedWork W2091308077 @default.
• W4224249124 hasRelatedWork W2110010918 @default.
• W4224249124 hasRelatedWork W2126741950 @default.
• W4224249124 hasRelatedWork W2510298210 @default.
• W4224249124 hasRelatedWork W2890853704 @default.
• W4224249124 hasRelatedWork W2983725837 @default.
• W4224249124 hasRelatedWork W3092519087 @default.
• W4224249124 hasVolume "63" @default.
• W4224249124 isParatext "false" @default.
• W4224249124 isRetracted "false" @default.

• next